We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02608125
Recruitment Status : Terminated (focus portfolio on immune-mediated diseases)
First Posted : November 18, 2015
Last Update Posted : December 24, 2020
Sponsor:
Information provided by (Responsible Party):
Principia Biopharma, a Sanofi Company

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a multi-center, open label, non-randomized Phase 1 study, to be conducted in two parts, Part A, and Part B. Part A in solid tumors included the dose escalation phase for evaluating the safety and tolerability profile of PRN1371, a FGFR 1-4 Kinase inhibitor. Part B is the Cohort Expansion phase in patients with metastatic urothelial carcinoma to further evaluate safety and tolerability, preliminary activity, PK, and PD in patients with FGFR genetic alterations.

Condition or disease Intervention/treatment Phase
Solid Tumors Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter Drug: PRN1371 Phase 1

Detailed Description:
The protocol specifies rules for dose-limiting toxicity and a maximum tolerated dose (MTD). To gain further experience with the MTD, and/or at some lower optimal biologic dose level, an expansion cohort (Part B) enrolled patients with metastatic urothelial carcinoma with fibroblast growth factor receptor (FGFR) 1, 2, 3 or 4 genetic alterations.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Cohort in Patients With Metastatic Urothelial Carcinoma With FGFR 1, 2, 3, or 4 Genetic Alterations
Actual Study Start Date : October 28, 2015
Actual Primary Completion Date : June 23, 2020
Actual Study Completion Date : June 23, 2020

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: PRN1371
Drug: PRN1371
 Drug: PRN1371


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Incidence of treatment related Grade 3 and/or Grade 4 adverse events, defined as dose limiting toxicities, for the doses of PRN1371 [ Time Frame: 28 days on average ]

Secondary Outcome Measures :
  1. Pharmacokinetic profile of PRN1371 including area under the serum concentration-time curve [ Time Frame: Days 1 and 15 ]
  2. Pharmacokinetic profile of PRN1371 including maximum serum concentration [ Time Frame: Days 1 and 15 ]
  3. Pharmacokinetic profile of PRN1371 including time to maximum serum concentration [ Time Frame: Days 1 and 15 ]
  4. Pharmacodynamic profile of PRN1371 including the effect of PRN1371 on phosphate levels [ Time Frame: While being treated with PRN1371 (expected average of 16 weeks) ]
  5. Pharmacodynamic profile of PRN1371 including the effect of PRN1371 on calcium levels [ Time Frame: While being treated with PRN1371 (expected average of 16 weeks) ]
  6. Pharmacodynamic profile of PRN1371 including the effect of PRN1371 on serum FGF23 (Part A only) levels [ Time Frame: While being treated with PRN1371 (expected average of 16 weeks) ]
  7. Objective response rate (ORR) as measured by RECIST v1.1 in patients treated with PRN1371 [ Time Frame: Every 8 weeks while being treated with PRN1371 (expected average of 16 weeks) ]
  8. Duration of response in patients treated with PRN1371 [ Time Frame: Every 8 weeks while being treated with PRN1371 (expected average 16 weeks) ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years
  • Histological or cytological documentation of an advanced solid tumor
  • Subject must have metastatic or recurrent disease and have failed first-line systemic treatment, and if indicated, failed approved second-line therapy, and for whom no standard therapy options are anticipated to result in a durable remission
  • Subject must have evaluable, progressive, and measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, Version 1.1
  • Adequate bone marrow, liver, and renal function
  • Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

For Part B (expansion) in subjects metastatic urothelial carcinoma:

  • The patient's tumor has been evaluated and prospectively identified as having FGFR 1, 2, 3, or 4 genetic alterations.

Exclusion Criteria:

  • Patients who have received adequate prior treatment with a highly selective FGFR inhibitor
  • Patients with other major uncontrolled medical conditions, e.g., recent myocardial infarction, stroke, diabetes, active hepatitis
  • Patients who have received prior systemic anticancer therapy ≤ 3 weeks prior to study start (6 weeks for nitrosourea, antibodies, or mitomycin-C)
  • Patients diagnosed with another primary malignancy within 3 years prior to study start, with the exception of adequately treated basal cell carcinoma, squamous cell carcinoma, or other non-melanomatous skin cancer, or carcinoma in situ of the uterine cervix
  • Patients with glioblastoma multiforme
  • Patient has a primary neoplasm of the brain or known uncontrolled metastases to the central nervous system (CNS).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02608125


Locations
Layout table for location information
United States, California
UCSF Helen Diller Family Comprehensive Cancer Cener
San Francisco, California, United States, 94115
United States, Maryland
Johns Hopkins Medicine
Baltimore, Maryland, United States, 21205
United States, North Carolina
Wake Forest University Health Sciences Medical Center
Winston-Salem, North Carolina, United States, 27157
United States, Tennessee
Tennessee Oncology, Sarah Canon Research Institute
Nashville, Tennessee, United States, 37203
United States, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Spain
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital
Barcelona, Spain, 08035
Hospital General Universitario de Elche
Elche, Spain, 03203
Hospital Universitario Ramon y Cajal
Madrid, Spain, 28034
START Madrid-FJD Fundacion Jiminez Diaz
Madrid, Spain, 28040
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
START Madrid-CIOCC, Centro Integral Oncológico Clara Campal
Madrid, Spain, 28050
Hospital Virgen del Rocio
Seville, Spain, 41013
Sponsors and Collaborators
Principia Biopharma, a Sanofi Company
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Principia Biopharma, a Sanofi Company
ClinicalTrials.gov Identifier: NCT02608125    
Other Study ID Numbers: PRN1371-001
First Posted: November 18, 2015    Key Record Dates
Last Update Posted: December 24, 2020
Last Verified: December 2020
Keywords provided by Principia Biopharma, a Sanofi Company:
FGFR
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms